Circio raises NOK 200 million towards in vivo CAR-T programme
Circio Holding has successfully completed a private placement raising gross proceeds to the company of approx. NOK 200 ($21) million, through the allocation of 16,865,000 new shares.
The Offer Price corresponds to a 9% discount to the volume weighted average share price (VWAP) quoted for trade in the company’s shares on the Oslo Stock Exchange on 14 September 2026.
“The new capital will be dedicated towards Circio’s circular RNA in vivo CAR-T cell therapy programme, an area of very high industry interest that has attracted substantial recent deal activity by big pharma,” said Dr Erik Digman Wiklund, CEO of Circio.
“By securing this additional funding during a period of strong momentum for both in vivo CAR-T and circular RNA, Circio can now broaden and accelerate the circVec cell therapy programme. This will include selecting and securing access to critical complementary vector and delivery technologies.
“The latest round comes on top of previous financings directed towards circVec platform development and our gene therapy programme, and brings the total capital raised by Circio during 2026 to NOK 820 million ($88 million). The 2030 cash runway remains in place, but with broadened R&D activities and an expanded ambition level.”
Specifically, the new funding will allow Circio to complete the screening and selection of DNA vector and T-cell targeted LNP-delivery systems currently ongoing in more than 10 active R&D collaborations. The company says these complementary technologies are essential components to establish a complete circVec in vivo CAR-T therapeutic concept.
Circio intends to secure access to the selected technologies via future in-licensing, technology acquisition or M&A transactions.
